The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Wendy Stock and Adam DuVall.
Connection Strength

2.278
  1. Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered! JCO Oncol Pract. 2022 07; 18(7):479-487.
    View in: PubMed
    Score: 0.726
  2. American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026 Jul 14; 10(13):4671-4708.
    View in: PubMed
    Score: 0.244
  3. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
    View in: PubMed
    Score: 0.200
  4. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420.
    View in: PubMed
    Score: 0.172
  5. Reduced-dose pegylated asparaginase reliably achieves therapeutic levels in adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma. Br J Haematol. 2026 Oct 15.
    View in: PubMed
    Score: 0.062
  6. MCL1 inhibition exerts potent antileukemic activity by restoring apoptosis in T-lineage acute lymphoblastic leukemia. Blood Neoplasia. 2026 Nov; 3(4):100302.
    View in: PubMed
    Score: 0.062
  7. Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
    View in: PubMed
    Score: 0.061
  8. Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors. Haematologica. 2026 Jul 01; 111(7):2451-2456.
    View in: PubMed
    Score: 0.059
  9. Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
    View in: PubMed
    Score: 0.058
  10. Feasibility of Symptom Burden Assessments and Early Palliative Care Integration in an Adolescent and Young Adult Leukemia Clinic. J Adolesc Young Adult Oncol. 2026 Oct; 15(5):378-383.
    View in: PubMed
    Score: 0.058
  11. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 08 14; 15(1):138.
    View in: PubMed
    Score: 0.057
  12. Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
    View in: PubMed
    Score: 0.057
  13. Real-world performance of the CALGB 10403 regimen in young adults in the United States. Blood Neoplasia. 2025 Aug; 2(3):100111.
    View in: PubMed
    Score: 0.056
  14. CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
    View in: PubMed
    Score: 0.055
  15. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
    View in: PubMed
    Score: 0.054
  16. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 06; 65(6):864-867.
    View in: PubMed
    Score: 0.052
  17. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.051
  18. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 04; 204(4):1238-1242.
    View in: PubMed
    Score: 0.051
  19. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.050
  20. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
    View in: PubMed
    Score: 0.047
  21. Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. J Assist Reprod Genet. 2022 Aug; 39(8):1733-1738.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.